A rare genetic mutation has brought into sharp focus the profound impact of inherited cancer risks on individuals and families. Tracy Hutchinson, whose family has been significantly affected by multiple cancer diagnoses over decades, has discovered she carries a rare variant of the TP53 gene, placing her at a near 100 per cent lifetime risk of developing cancer.
This specific variant leads to a condition called Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition syndrome. Unlike more commonly known mutations like BRCA1 and BRCA2, LFS is rarer but significantly increases the likelihood of developing various cancers at a younger age. For individuals with this mutation, there is approximately a 50 per cent chance of developing cancer before the age of 30, and almost a certainty over a lifetime, affecting virtually any part of the body.
Ms Hutchinson's journey to diagnosis began after a distressing pattern of cancers within her family. Her sister was diagnosed with acute lymphoblastic leukaemia in 1990, followed by her mother's breast cancer diagnosis shortly after. Subsequent years saw her father battling bowel cancer, her mother facing further breast cancer and later oesophageal cancer, and another sister developing fast-growing triple-negative breast cancer in 2020. This extensive family history prompted genetic testing, initially for BRCA mutations, which came back negative. Further investigation led to testing for the TP53 mutation, which confirmed the presence of Li-Fraumeni syndrome in her sister and subsequently in Ms Hutchinson herself in 2022.
Following her diagnosis, Ms Hutchinson underwent preventative measures, including a double mastectomy, during which early forms of cancer were detected in her left breast. She now participates in a clinical trial in Australia, which involves annual whole-body MRIs to detect tumours early. This intensive screening regimen also includes yearly skin checks, annual blood tests, and biennial endoscopies and colonoscopies, highlighting the comprehensive and ongoing surveillance required for individuals with LFS. These proactive measures have already led to the discovery of a benign brain tumour and the removal of precancerous polyps.
For the NHS, managing such rare and high-risk genetic conditions presents unique challenges and opportunities. Genetic counselling and testing are crucial for identifying at-risk individuals and families. The implications extend to developing robust screening protocols, similar to those in the Australian trial, to ensure early detection, which is paramount for improving outcomes in patients with LFS. This also means supporting patients through the significant psychological burden of living with such a high cancer risk, often referred to as 'scanxiety' around screening times.
NICE guidelines continually evolve to incorporate the latest understanding of genetic predispositions to cancer, aiming to ensure equitable access to appropriate screening and preventative strategies across the UK. While whole-body MRI is not routinely available for LFS patients on the NHS, specialist centres do offer targeted surveillance based on individual risk profiles and the specific mutations identified.
Source: Tracy Hutchinson via a personal account